ARPA-H, part of HHS, has earmarked up to $142 million for 10 research projects building the tools, data, and infrastructure needed to tackle treatment resistance.

During a live event, Jeffrey V. Matous, MD, discussed bispecific antibody treatment efficacy and safety in advanced multiple ...

Fully cell-free process aims to democratize personalized cancer therapeutics with shorter turnaround and negligible bioburden ...

A global study led by researchers at the School of Clinical Sciences at Monash Health, Monash University, has found that ...

Neuronetics Inc. (NASDAQ:STIM) is one of the best-performing NASDAQ stocks according to analysts. On June 10, Neuronetics ...

Shorter-form messaging seems to be preferable for recruiting participants to enroll in clinical trials, according to a research letter published online June 25 in the Journal of the American Medical ...

Under the new leadership of Marty Makary, the FDA should focus more attention on the critical role of real-world clinical data — such as from health insurance databases — in the ongoing assessment of ...